Lobular Breast Carcinoma
13
4
7
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (13)
Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT
Biomarkers to Detect Endocrine Therapy Resistance
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
CDH1 Germline Mutations in Lobular Breast Cancer
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients
Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours
18F FES-PET/MRI for Tailoring Treatment of Luminal a and Lobular Breast Cancer
Living Well After Breast Surgery
Broccoli Sprout Extract in Treating Patients With Breast Cancer
Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy